ATC Group: J05AJ04 Cabotegravir

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J05AJ04 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J05 Antivirals for systemic use
3 J05A Direct acting antivirals
4 J05AJ Integrase inhibitors
5 J05AJ04 Cabotegravir

Active ingredients in J05AJ04

Active Ingredient

Cabotegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle.

Related product monographs

Document Type Information Source  
 APRETUDE Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)
 APRETUDE Prolonged-release suspension for injection MPI, EU: SmPC European Medicines Agency (EU)
 VOCABRIA Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)
 VOCABRIA Film-coated tablet MPI, US: SPL/PLR FDA, National Drug Code (US)
 VOCABRIA Prolonged-release suspension for injection MPI, EU: SmPC European Medicines Agency (EU)

Medicines in this ATC group

United States (US)

Austria (AT)

Canada (CA)

Croatia (HR)

Estonia (EE)

Finland (FI)

France (FR)

Ireland (IE)

Israel (IL)

Italy (IT)

Japan (JP)

Lithuania (LT)

Nigeria (NG)

Poland (PL)

Romania (RO)

Spain (ES)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.